GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » ROE %

Taysha Gene Therapies (Taysha Gene Therapies) ROE % : -149.46% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Taysha Gene Therapies's annualized net income for the quarter that ended in Mar. 2024 was $-96.24 Mil. Taysha Gene Therapies's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $64.39 Mil. Therefore, Taysha Gene Therapies's annualized ROE % for the quarter that ended in Mar. 2024 was -149.46%.

The historical rank and industry rank for Taysha Gene Therapies's ROE % or its related term are showing as below:

TSHA' s ROE % Range Over the Past 10 Years
Min: -2137   Med: -197.36   Max: -47.79
Current: -2137

During the past 5 years, Taysha Gene Therapies's highest ROE % was -47.79%. The lowest was -2,137.00%. And the median was -197.36%.

TSHA's ROE % is ranked worse than
99.19% of 1350 companies
in the Biotechnology industry
Industry Median: -43.845 vs TSHA: -2137.00

Taysha Gene Therapies ROE % Historical Data

The historical data trend for Taysha Gene Therapies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies ROE % Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- -47.79 -100.68 -344.67 -294.04

Taysha Gene Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1,479.02 -149.46

Competitive Comparison of Taysha Gene Therapies's ROE %

For the Biotechnology subindustry, Taysha Gene Therapies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taysha Gene Therapies's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's ROE % distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's ROE % falls into.



Taysha Gene Therapies ROE % Calculation

Taysha Gene Therapies's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-111.566/( (0.949+74.937)/ 2 )
=-111.566/37.943
=-294.04 %

Taysha Gene Therapies's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-96.244/( (74.937+53.849)/ 2 )
=-96.244/64.393
=-149.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Taysha Gene Therapies  (NAS:TSHA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-96.244/64.393
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-96.244 / 13.644)*(13.644 / 162.865)*(162.865 / 64.393)
=Net Margin %*Asset Turnover*Equity Multiplier
=-705.39 %*0.0838*2.5292
=ROA %*Equity Multiplier
=-59.11 %*2.5292
=-149.46 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-96.244/64.393
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-96.244 / -96.244) * (-96.244 / -97.32) * (-97.32 / 13.644) * (13.644 / 162.865) * (162.865 / 64.393)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9889 * -713.28 % * 0.0838 * 2.5292
=-149.46 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Taysha Gene Therapies ROE % Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Executives
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long director KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii 10 percent owner C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc. 10 percent owner 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc. 10 percent owner 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape director C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235

Taysha Gene Therapies (Taysha Gene Therapies) Headlines

From GuruFocus

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock

By Value_Insider Value_Insider 10-25-2022